This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
CVS vs. UNH: Which Health Insurance Stock Has More Upside Now?
by Moumi Mondal
UnitedHealth Group's stronger six-month return, improving UnitedHealthcare and Optum results and attractive valuation make it the better buy.
UNHNegative Net Change CVSNegative Net Change
medical medical-devices
4 PEG-Based Value Stocks to Buy as Investors Look Beyond AI
by Urmimala Biswas
Four value stocks stand out as investors look beyond AI, using PEG ratios, earnings growth and valuation metrics to find potential winners.
DGPositive Net Change ALLPositive Net Change MTCHPositive Net Change NVSTNegative Net Change
artificial-intelligence finance medical medical-devices retail tech-stocks
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
by Zacks Equity Research
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
NTRAPositive Net Change WSTPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
by Debanjana Dey
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
DVAPositive Net Change OPCHNegative Net Change AVAHPositive Net Change LFSTNegative Net Change
medical medical-devices
CVRx Secures Devoted Health Coverage for Barostim Therapy
by Zacks Equity Research
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
CVRXPositive Net Change COONegative Net Change WSTPositive Net Change GMEDPositive Net Change
medical medical-devices
Microsoft (MSFT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MSFTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
McKesson to Acquire Precision Medicine Group to Strengthen Services
by Zacks Equity Research
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
MCKPositive Net Change WSTPositive Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock Up
by Zacks Equity Research
VEEV's Q2 fiscal 2027 earnings and revenues top estimates, while strong Vault CRM momentum and a raised full-year outlook drive shares higher.
VEEVPositive Net Change COONegative Net Change WSTPositive Net Change GMEDPositive Net Change
earnings medical medical-devices
Is This the Right Time to Hold Medtronic Stock in Your Portfolio?
by Zacks Equity Research
MDT's Cardiovascular gains and renal denervation growth offer upside, but tariffs and currency headwinds cloud its outlook.
MDTNegative Net Change TFXNegative Net Change GMEDPositive Net Change VCYTNegative Net Change
medical medical-devices
How CVS' Pharmacy & Consumer Wellness Is Positioned for H2 2026
by Moumi Mondal
CVS Health carries strong pharmacy momentum into H2 2026, with rising prescription volume, Rite Aid gains and higher profit.
CVSNegative Net Change DVAPositive Net Change CAHNegative Net Change
medical medical-devices